Adaptive Biotechnologies (ADPT) Is Up 10.1% After New Pfizer TCR-AI Collaboration Milestone Deal - What's Changed

• In mid-December 2025, Adaptive Biotechnologies announced two non-exclusive agreements with Pfizer to apply its T-cell receptor discovery platform to rheumatoid arthritis and to license its extensive TCR–antigen binding dataset for Pfizer’s AI and machine learning-driven drug discovery efforts.
• The deals underscore the commercial potential of Adaptive’s immune repertoire data, with the rheumatoid arthritis collaboration alone carrying up to about US$890 million in possible milestones alongside multi-year data licensing fees.
• We’ll now explore how this Pfizer collaboration, especially the up to about US$890 million milestone structure, may reshape Adaptive’s investment narrative.

These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Adaptive Biotechnologies Investment Narrative Recap

To own Adaptive Biotechnologies, you need to believe its immune sequencing and TCR data can support durable, high-value pharma and diagnostic partnerships while the company moves closer to consistent profitability. The new Pfizer agreements highlight the monetization potential of Immune Medicine and may partially offset the Genentech termination risk, but the biggest near term swing factor remains whether Adaptive can keep improving cash burn and avoid needing dilutive capital in a business that is still unprofitable overall.

The Pfizer collaboration stands out among recent announcements because it directly tests whether Adaptive’s TCR discovery platform and antigen mapping can become a repeatable, high-margin pharma partnership model. While clonoSEQ’s growing clinical footprint and improved MRD guidance support the core diagnostics catalyst, these non exclusive Pfizer deals reinforce the longer term thesis that Adaptive’s immune repertoire data can translate into multiple paid collaborations, which matters more now that one major pharma relationship is winding down.

Yet behind the headline milestones, investors should be aware of the risk that prolonged unprofitability and cash burn could still lead to...

Read the full narrative on Adaptive Biotechnologies (it's free!)

Adaptive Biotechnologies' narrative projects $350.6 million revenue and $49.8 million earnings by 2028. This requires 19.5% yearly revenue growth and a $171.0 million earnings increase from $-121.2 million today.

Uncover how Adaptive Biotechnologies' forecasts yield a $19.57 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community fair value estimates range from US$7.88 to US$21, showing just how far apart views on Adaptive can be. Against that backdrop, the Pfizer TCR and data deals highlight how differently people may weigh the potential of Immune Medicine partnerships relative to the company’s ongoing losses and cash needs, so it is worth comparing several viewpoints before forming your own.

Explore 3 other fair value estimates on Adaptive Biotechnologies - why the stock might be worth less than half the current price!

Build Your Own Adaptive Biotechnologies Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Adaptive Biotechnologies research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Adaptive Biotechnologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Adaptive Biotechnologies' overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.
• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com